A second opinion was sought if LV function was assessed as <40%. LV function by cardiac MRI was determined by standard semi-automated endocardial contouring at end diastole and end systole using Siemens Syngovia software. The cut off for severe LV dysfunction was <35% and >55% for normal.

Results 12301 TTE and 398 CMR scans were performed in the study period. 120 patients met inclusion criteria with TTE and CMR within 30 days. Reasons for exclusion included missing data (n=2), reversible cause for LV dysfunction (n=1) and poor endocardial definition (n=4) leaving a study population of 113 patients. LVEF by TTE and CMR (figure 1) were strongly correlated ($R=0.85$, $p < 0.001$). Bland Altman analysis demonstrated a signal of systematic bias with LVEF by CMR 4.4% higher than TTE (mean bias 4.4%, 95% CI -0.3 to 9.0, $p = 0.06$). Severe LV function on both TTE and CMR were in accordance in 91% of cases. Normal LV function by TTE and CMR was in accordance in 85% of cases.

Conclusion These results show good correlation of LVEF by TTE and CMR with the latest generation of scanners with a signal of systematic bias where CMR LVEF reads 4.4% higher than TTE. These results are used locally to guide clinical decision making and form part of on-going quality assurance processes. Further work to improve agreement between modalities is required.

Conflict of Interest None

173

PREVALENCE OF ECHOCARDIOGRAPHIC ABNORMALITIES IN PATIENTS HOSPITALISED WITH COVID-19

Dennis Chong, Issam Seyala, Muhammad Hamza, Sundes Shah, Khaled Makhoulf, Wai-Chung Wong, Gavin Bridgwood, Bethany Griffith, Diego Maseda. *Mid Cheshire Hospitals NHS Foundation Trust, Crewe, UK*

10.1136/heartjnl-2021-BCS.170

Introduction COVID-19 is a multi-systemic disease and cardiac involvement has been widely recognised. Impaired cardiac function is linked to worse prognosis and has important implications on patient management. Evidence-based recommendations to guide selection of COVID-19 patients for transthoracic echocardiogram (TTE) are lacking, and there are concerns regarding unnecessary exposure of sonographers to infection risks.

Purpose 1. To determine the prevalence and nature of abnormal TTE findings in patients who underwent TTE within 6 months of admission to our centre with COVID-19 infection. 2. To determine if specific clinical characteristics were predictors of an abnormal TTE finding.

Methods A retrospective cohort study of all patients admitted to a single hospital with confirmed COVID-19 (through PCR) from 27/03/2020 to 21/06/2020, cross matched with the local TTE database. Data on patient demographics, TTE indication, biochemical markers, selected co-morbidities, ITU admission and mortality were collected. Patients with abnormal TTE were defined by the presence of left ventricular systolic dysfunction (LVSD), right ventricular systolic dysfunction (RVSD), regional wall motion abnormalities (RWMA) or pericardial effusion. Where available, patients with abnormal TTE were compared to previous TTE results to determine if findings

Abstract 173 Table 1

Clinical characteristic	Abnormal TTE (n=31)	Normal TTE (n=39)	p value
Age	73±9.5	70±14.0	0.201
Sex	58%	45%	0.344
CRP	97±74	117±123	0.419
Lymphocyte count	0.91±0.39	0.84±0.47	0.551
Raised HS-troponin*	79%	44%	0.045
Hypertension	46%	36%	0.466
Diabetes mellitus	30%	37%	0.621
Ischaemic heart disease	30%	13%	0.09
ITU admission	16%	26%	0.383
Mortality	34%	18%	0.18

*Data available for 37 patients

were new. If LVSD was previously present, any worsening in category of severity was considered significant. Unpaired t test and Fisher's exact test were used for between group statistical analysis.

Results We identified 71 (12%) patients who underwent TTE from 597 patients admitted with a diagnosis of COVID-19. The mean age was 71 (42-93) years and 37 (52%) were male. 18 (25%) patients died within the admission and 15 (21%) required ITU care. The most frequent indications for TTE were suspected heart failure (42%), endocarditis (17%), MI (13%), valvular dysfunction (7%) and myopericarditis/effusion (7%). A total of 33 (46%) patients had an abnormal TTE. Of these, 30 (91%) were new findings. LVSD was detected in 26 (37%) cases: 5 (7%) mild, 8 (11%) moderate and 12 (17%) severe. RVSD was detected in 12 (17%), pericardial effusion in 9 (13%) and RWMA in 10 (14%). The only clinical characteristic that predicted an abnormal TTE was raised high sensitivity troponin (table 1). There was a trend towards an abnormal TTE in patients with known ischaemic heart disease (30% Vs 13%, $p = 0.09$). Increased mortality was observed in the abnormal TTE group (34% Vs 18%) although this did not reach statistical significance.

Conclusions There was a high prevalence of significant TTE abnormalities in patients admitted to our hospital with COVID-19 where TTE was clinically indicated. Our cohort had a predominance for LVSD rather than RVSD compared to other studies. Raised high sensitivity troponin level was a predictor of an abnormal TTE and may guide selection of COVID-19 patients for TTE.

Conflict of Interest None to declare

174

CARDIAC MAGNETIC RESONANCE IMAGING IN PATIENTS WITH CHEST PAIN, TROPONIN INCREASE AND UNOBSTRUCTED CORONARY ARTERIES; A STUDY OF REAL-WORLD ADHERENCE TO GUIDELINES FROM A LARGE UK DISTRICT GENERAL HOSPITAL DURING THE COVID-19 PANDEMIC

Oluwaseun Olubodun, Shereen Azeez, Karishma Dhera, Harriet Shearman, Andrew Elkington, Sacha Bull. *Royal Berkshire Hospital, UK*

10.1136/heartjnl-2021-BCS.171

Background The 2020 ESC Taskforce guidelines made a level I recommendation for the use of cardiac magnetic resonance (CMR) in patients with suspected myocardial infarction with non-obstructive coronary arteries (MINOCA). CMR is a powerful diagnostic tool that can discriminate between myocardial infarction, Takotsubo and myocarditis; myocardial